Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S has announced the progression of its share repurchase program, initiated on February 6, 2024, detailing the acquisition of 1,230,000 B shares at an average price of DKK 855.73 each, totaling DKK 1,052,551,945 in value. This buyback is part of a larger 12-month plan to repurchase up to DKK 20 billion worth of shares, underlining the company’s ongoing commitment to return value to shareholders. Novo Nordisk, a global leader in healthcare with a focus on defeating chronic diseases, continues to strengthen its market position and investor confidence.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
